1-20 of 43
Sarit E. Assouline
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Clinical Trials & Observations
Arnon P. Kater, Rosemary Anne Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn Owen, Sarit E. Assouline, Nicole Lamanna, Tadeusz Robak, Prof., Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Anton W. Langerak, Brenda Chyla, Relja Popovic, Yanwen Jiang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F Seymour
Journal: Blood
Blood blood.2024025525.
https://doi.org/10.1182/blood.2024025525
Published: 2025
Includes: Supplemental data
Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Clinical Trials & Observations
Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Stephen J. Schuster, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Yoon Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Derrick Kaufman, Antonia Kwan, Elicia Penuel, Christopher R. Bolen, Lihua E. Budde
Journal: Blood
Blood (2025) 145 (7): 708–719.
https://doi.org/10.1182/blood.2024025454
Published: 2025
Includes: Supplemental data
Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Adam J. Olszewski, Mariana Bastos-Oreiro, Sarit E. Assouline, Izidore S. Lossos, Catherine Diefenbach, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Nirav N. Shah, Ronan Foley, Daniel J Hodson, Sneha Makadia, Song Pham, Elicia Penuel, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 989.
https://doi.org/10.1182/blood-2024-194581
Published: 2024
Journal Articles

Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care

Chantal Cassis, Victoria Korsos, Saima Ahmed, Vasiliki Bitzas, Sheena Heslip, Sarah Matarasso Greenfeld, Rayan Kaedbey, Sarit E. Assouline
Journal: Blood
Blood (2024) 144 (Supplement 1): 2291.
https://doi.org/10.1182/blood-2024-209158
Published: 2024
Journal Articles

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Sita D. Bhella, Allison M. Wilkin, Katrina Hueniken, Abi Vijenthira, Michael Sebag, Peng Wang, Lisa K Hicks, Annette E. Hay, Arleigh McCurdy, Seyed Hosseini-Moghaddam, Donna Reece, Sarit E. Assouline, Graeme Andrew McCrae Fraser, Amaris K Balitsky, Joy Mangel, Carolyn Owen, Anthony Reiman, Laurie H. Sehn, Heather J. Sutherland, Corey Arnold, Tamara Leite, Erinn McCarthy, Curtis Cooper, Marc-Andre Langlois, C. Arianne Buchan
Journal: Blood
Blood (2024) 144 (Supplement 1): 286.
https://doi.org/10.1182/blood-2024-211949
Published: 2024
Journal Articles

Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Katharine L. Lewis, Wojciech Jurczak, Gareth P. Gregory, Constantine S. Tam, Won Seog Kim, Eliza A. Hawkes, Franck Morschhauser, Sarit E. Assouline, Geoffrey Shouse, Petra Langerbeins, Monica Tani, Young Rok Do, Bruce D. Cheson, Catherine S. Diefenbach, Craig A. Portell, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy
Journal: Blood
Blood (2024) 144 (Supplement 1): 4501.
https://doi.org/10.1182/blood-2024-199281
Published: 2024
Journal Articles

The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care

Victoria Korsos, Saima Ahmed, Sheena Heslip, April Shamy, Rayan Kaedbey, Sarah Matarasso Greenfeld, Chantal Cassis, Sarit E. Assouline
Journal: Blood
Blood (2024) 144 (Supplement 1): 3670.
https://doi.org/10.1182/blood-2024-208976
Published: 2024
Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Maria Agustina Perusini, Claire Andrews, Eshetu G Atenafu, Sarit E. Assouline, Joseph Brandwein, Mohammad Jarrar, Steven M. Chan, Signy Chow, Dina Khalaf, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Gizelle Popradi, Waleed Sabry, Lalit Saini, David Sanford, Lynn Savoie, Aaron Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai
Journal: Blood
Blood (2024) 144 (Supplement 1): 1506.
https://doi.org/10.1182/blood-2024-204004
Published: 2024
Journal Articles

Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)

Marc-Etienne Beaudet, Natasha Szuber, Hanane Moussa, Michaël Harnois, Sarit E. Assouline, Lambert Busque
Journal: Blood
Blood (2024) 144 (Supplement 1): 533.
https://doi.org/10.1182/blood-2024-204342
Published: 2024
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett
Journal: Blood
Blood (2024) 144 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2024-197902
Published: 2024
Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Mazyar Shadman, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit E. Assouline, Laurie H. Sehn, John Kuruvilla, Pratyush Giri, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Connie Y. Ma, Samuel Tracy, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2024-197897
Published: 2024
Journal Articles

Clinical Approach to “Pathologically Ambiguous Follicular Lymphoma”: A Real-World Study

Sarah Matarasso Greenfeld, Svetlana Dmitrienko, Ian Shrier, Sarit E. Assouline
Journal: Blood
Blood (2024) 144 (Supplement 1): 6346.
https://doi.org/10.1182/blood-2024-207584
Published: 2024
Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Nancy L. Bartlett, Laurie H. Sehn, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung-Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Antonia Kwan, Elicia Penuel, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 1645.
https://doi.org/10.1182/blood-2024-194612
Published: 2024
Journal Articles

A Comparison of the Timing of Treatment Initiation for Older Versus Younger Patients with Follicular Lymphoma

Sarah Matarasso Greenfeld, Ian Shrier, Sarit E. Assouline
Journal: Blood
Blood (2024) 144 (Supplement 1): 4419.
https://doi.org/10.1182/blood-2024-207223
Published: 2024
Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Clinical Trials & Observations
Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Journal: Blood
Blood (2024) 143 (9): 822–832.
https://doi.org/10.1182/blood.2023022348
Published: 2024
Includes: Supplemental data
Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-142859
Published: 2020
Journal Articles

Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial

Sarit E Assouline, MD MSc, Won Seog Kim, MD PhD, Laurie H. Sehn, MDMPH, Stephen J. Schuster, MD, Chan Yoon Cheah, MBBS, Loretta J. Nastoupil, MD, Mazyar Shadman, Sung-Soo Yoon, MD PhD, Matthew J Matasar, MD, Catherine Diefenbach, MD, Gareth P. Gregory, Nancy L. Bartlett, MD, Michael C. Wei, Michelle Y. Doral, Shen Yin, Raluca Negricea, Chi-Chung Li, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-135839
Published: 2020
Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-142990
Published: 2020
Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J Matasar, MD, Chan Yoon Cheah, MBBS, Dok Hyun Yoon, Sarit E Assouline, MD MSc, Nancy L. Bartlett, MD, Matthew Ku, Pratyush Giri, Anna Johnston, MBBS (Hons 1), FRACP, FRCPA, Ian W. Flinn, MD PhD, Andre H. Goy, MD, Dimitrios Tzachanis, MD PhD, Carol O'Hear, Shen Yin, Iris To, Kati Sarouei, Chi-Chung Li, Brendan C. Bender, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135818
Published: 2020
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020